109 related articles for article (PubMed ID: 22151005)
1. Glucocorticoid replacement therapy and fibrinolysis in patients with hypopituitarism.
Peacey SR; Wright D; Aye M; Moisey R
Clin Endocrinol (Oxf); 2012 Jul; 77(1):94-8. PubMed ID: 22151005
[TBL] [Abstract][Full Text] [Related]
2. Conventional glucocorticoid replacement overtreats adult hypopituitary patients with partial ACTH deficiency.
Agha A; Liew A; Finucane F; Baker L; O'Kelly P; Tormey W; Thompson CJ
Clin Endocrinol (Oxf); 2004 Jun; 60(6):688-93. PubMed ID: 15163331
[TBL] [Abstract][Full Text] [Related]
3. Optimizing glucocorticoid replacement therapy in severely adrenocorticotropin-deficient hypopituitary male patients.
Behan LA; Rogers B; Hannon MJ; O'Kelly P; Tormey W; Smith D; Thompson CJ; Agha A
Clin Endocrinol (Oxf); 2011 Oct; 75(4):505-13. PubMed ID: 21521342
[TBL] [Abstract][Full Text] [Related]
4. Low-dose hydrocortisone replacement therapy is associated with improved bone remodelling balance in hypopituitary male patients.
Behan LA; Kelleher G; Hannon MJ; Brady JJ; Rogers B; Tormey W; Smith D; Thompson CJ; McKenna MJ; Agha A
Eur J Endocrinol; 2014 Jan; 170(1):141-50. PubMed ID: 24123094
[TBL] [Abstract][Full Text] [Related]
5. Acute effect of increasing glucocorticoid replacement dose on cardiovascular risk and insulin sensitivity in patients with adrenocorticotrophin deficiency.
Petersons CJ; Mangelsdorf BL; Thompson CH; Burt MG
J Clin Endocrinol Metab; 2014 Jun; 99(6):2269-76. PubMed ID: 24606100
[TBL] [Abstract][Full Text] [Related]
6. Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly.
Sartorio A; Cattaneo M; Bucciarelli P; Bottasso B; Porretti S; Epaminonda P; Faglia G; Arosio M
Exp Clin Endocrinol Diabetes; 2000; 108(7):486-92. PubMed ID: 11083070
[TBL] [Abstract][Full Text] [Related]
7. Glucocorticoid replacement therapy is independently associated with reduced bone mineral density in women with hypopituitarism.
Ragnarsson O; Nyström HF; Johannsson G
Clin Endocrinol (Oxf); 2012 Feb; 76(2):246-52. PubMed ID: 21767286
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
Johansson JO; Landin K; Johannsson G; Tengborn L; Bengtsson BA
Thromb Haemost; 1996 Sep; 76(3):422-8. PubMed ID: 8883281
[TBL] [Abstract][Full Text] [Related]
9. Glucocorticoid replacement is associated with hypertriglyceridaemia, elevated glucose and higher non-HDL cholesterol and may diminish the association of HDL cholesterol with the -629C>A CETP promoter polymorphism in GH-receiving hypopituitary patients.
Dullaart RP; Schols JL; van der Steege G; Zelissen PM; Sluiter WJ; van Beek AP
Clin Endocrinol (Oxf); 2008 Sep; 69(3):359-66. PubMed ID: 18221399
[TBL] [Abstract][Full Text] [Related]
10. Prolonged hypocortisolemia in hydrocortisone replacement regimens in adrenocorticotrophic hormone deficiency.
Maguire AM; Ambler GR; Moore B; McLean M; Falleti MG; Cowell CT
Pediatrics; 2007 Jul; 120(1):e164-71. PubMed ID: 17576782
[TBL] [Abstract][Full Text] [Related]
11. Acute effects of glucocorticoids on endothelial fibrinolytic and vasodilator function in humans.
Dover AR; Hadoke PW; Walker BR; Newby DE
J Cardiovasc Pharmacol; 2007 Sep; 50(3):321-6. PubMed ID: 17878762
[TBL] [Abstract][Full Text] [Related]
12. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of haemostatic and fibrinolytic markers in patients with Cushing's syndrome and in patients with adrenal incidentaloma.
Ambrosi B; Sartorio A; Pizzocaro A; Passini E; Bottasso B; Federici A
Exp Clin Endocrinol Diabetes; 2000; 108(4):294-8. PubMed ID: 10961361
[TBL] [Abstract][Full Text] [Related]
14. Acquired prolactin deficiency (APD) after treatment for Cushing's disease is a reliable marker of irreversible severe GHD but does not reflect disease status.
Mukherjee A; Murray RD; Teasdale GM; Shalet SM
Clin Endocrinol (Oxf); 2004 Apr; 60(4):476-83. PubMed ID: 15049963
[TBL] [Abstract][Full Text] [Related]
15. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
16. The effects of growth hormone deficiency and replacement on glucocorticoid exposure in hypopituitary patients on cortisone acetate and hydrocortisone replacement.
Swords FM; Carroll PV; Kisalu J; Wood PJ; Taylor NF; Monson JP
Clin Endocrinol (Oxf); 2003 Nov; 59(5):613-20. PubMed ID: 14616886
[TBL] [Abstract][Full Text] [Related]
17. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women.
Koh KK; Mincemoyer R; Bui MN; Csako G; Pucino F; Guetta V; Waclawiw M; Cannon RO
N Engl J Med; 1997 Mar; 336(10):683-90. PubMed ID: 9041098
[TBL] [Abstract][Full Text] [Related]
18. Hydrocortisone replacement therapy in children and adolescents with hypopituitarism.
DeVile CJ; Stanhope R
Clin Endocrinol (Oxf); 1997 Jul; 47(1):37-41. PubMed ID: 9302370
[TBL] [Abstract][Full Text] [Related]
19. Levels of DHEA and DHEAS and responses to CRH stimulation and hydrocortisone treatment in chronic fatigue syndrome.
Cleare AJ; O'Keane V; Miell JP
Psychoneuroendocrinology; 2004 Jul; 29(6):724-32. PubMed ID: 15110921
[TBL] [Abstract][Full Text] [Related]
20. Acquired prolactin deficiency indicates severe hypopituitarism in patients with disease of the hypothalamic-pituitary axis.
Mukherjee A; Murray RD; Columb B; Gleeson HK; Shalet SM
Clin Endocrinol (Oxf); 2003 Dec; 59(6):743-8. PubMed ID: 14974916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
